Sepsis — the body's own immune response turning destructive in the face of an infection — kills an estimated 11 million people a year worldwide, and children carry a disproportionate share of that toll. In neonatal and pediatric intensive care units it remains one of the leading causes of death, and one of the hardest conditions to treat, because the damage is often done by the time the diagnosis is certain.
The clinical problem is timing. Early sepsis looks like a hundred other things — a fever, a fast heart rate, a child who is simply not themselves — and the standard response, broad-spectrum antibiotics and fluids, works best in the first hour. Once the immune cascade is fully engaged, the inflammation that was meant to fight the infection begins to damage organs, and treatment shifts from curing to supporting: ventilators, vasopressors, dialysis. It is this later stage that kills.
That gap is where a generation of startups has converged, betting that the inflammatory response itself can be attacked more directly than conventional medicine does.
TechCrunch profiles one of them, Efferon, which has set its sights on pediatric sepsis specifically. The company's stated ambition is to eradicate the condition's devastating toll on children — a goal that puts it at once in competition with, and alongside, the hospitals and researchers who have spent decades trying to move diagnosis earlier and treatment faster.
The obstacles are familiar. Sepsis is not one disease but a syndrome with many causes, so a therapy that works for one patient may not for the next. Trials are expensive and slow, in part because the patients who need treatment most are the hardest to enrol. And any new approach must prove, in children, that it is both safe and better than the care already in place.
None of that has discouraged the field; the size of the unmet need is too great. In pediatric intensive care, a treatment that reliably improves survival in septic shock would be among the most consequential advances in decades. The question is whether the biology cooperates.
